title: Trovafloxacin susceptibility of aerobic clinical bacterial isolates from Sweden.
abstract: Trovafloxacin susceptibility was studied in aerobic clinical isolates of bacterial pathogens from 5 microbiology laboratories in Sweden. Trovafloxacin and ciprofloxacin minimum inhibitory concentration (MIC) determinations were performed on 474 clinical isolates. Disk diffusion tests using trovafloxacin and ciprofloxacin 10 microg disks were performed on a total of 7142 clinical isolates (trovafloxacin). Susceptibility interpretations for trovafloxacin and ciprofloxacin were determined from MIC values and disk diffusion tests using species-related MIC-limits and zone diameter breakpoints. Eight of 12 gram-positive species groups were fully susceptible to trovafloxacin as judged by MIC tests. Trovafloxacin gave MIC50 values of 0.032 mg/l for S. aureus, 1.0 mg/l for MRSA, 0.064 mg/l for coagulase negative staphylococci, 1.0 mg/l for MRSE, 0.064 mg/l for S. saprophyticus, 0.125 mg/l for group A and group B streptococci, 0.064 mg/l for group C and G streptococci and S. pneumoniae, 0.25 mg/l for E. faecalis, and 16.0 mg/l for E. faecium. These MIC values were 4-16-fold lower than those of ciprofloxacin. Both MIC and disk tests showed similar levels of susceptibility among gram-negative isolates for trovafloxacin and ciprofloxacin. For most gram-negative species the trovafloxacin MIC50 values were similar to or slightly higher than those for ciprofloxacin. Trovafloxacin MIC values were much lower for Acinetobacter strains, but higher for P. mirabilis compared with ciprofloxacin. The favourable susceptibility levels of Swedish aerobic pathogens to trovafloxacin emphasize the potential of this drug for the treatment of serious infections.
authors.affiliation: Department of Laboratory Medicine, Karolinska Institute & Hospitals, Stockholm, Sweden.
authors.forename: M
authors.initials: M
authors.lastname: Rylander
authors.forename: M
authors.initials: M
authors.lastname: Walder
authors.forename: L
authors.initials: L
authors.lastname: Lind-Brandberg
authors.forename: P
authors.initials: P
authors.lastname: Larsson
authors.forename: E
authors.initials: E
authors.lastname: Törnqvist
authors.forename: T
authors.initials: T
authors.lastname: Monsen
authors.forename: G
authors.initials: G
authors.lastname: Kronvall
mesh_terms: D000890:Anti-Infective Agents / Q000494:pharmacology*; D001420:Bacteria, Aerobic / Q000187:drug effects*; D024841:Fluoroquinolones; D006801:Humans; D008826:Microbial Sensitivity Tests; D009287:Naphthyridines / Q000494:pharmacology*
chemical_list: D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D009287:Naphthyridines; C080163:trovafloxacin